A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults
Latest Information Update: 08 Jan 2024
At a glance
- Drugs MRNA-1647 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Moderna Therapeutics
Most Recent Events
- 11 Jan 2023 Status changed from active, no longer recruiting to completed.
- 08 Oct 2021 Planned End Date changed from 31 May 2022 to 31 Dec 2022.
- 08 Oct 2021 Planned primary completion date changed from 31 May 2022 to 31 Dec 2022.